Poster List

Print
Board #
ACUTE LEUKEMIA (AML, ALL)
1
STUDY OF FEW CYTOKINES GENES POLYMORPHISM AND EVOLUTION AFTER HSCT
D. Bratu
1,2, I Constantinescu1,2, A Moise1
1Hematology, Clinical Institute Fundeni, Romania
2Hematology, UMF Carol Davila, Romania
2
THE INFLUENCE OF HAPLOTYPE HLA-A3/A11 IN EVOLUTION AFTER HSCT
D. Bratu
1,2, I Constantinescu1,2, A Moise1
1Hematology, Clinical Institute Fundeni, Romania
2Hematology, UMF Carol Davila, Romania
3
AML CR 1 TRANSPLANTS WITH BU/CY CONDITIONING FROM A DEVELOPING COUNTRY – DOES IT MAKE ECONOMIC SENSE
S Damodar, K. S Nataraj, S Bhat, S Badiger
Haematology, Narayana Healt City/Mazumdar Shaw Cancer Center, India
4
OXIDATION OF PEROXIREDOXINS BY THIOREDOXIN INACTIVATION IS MEDIATED IN ARSENIC TRIOXIDE-INDUCED REACTIVE OXYGEN SPECIES FORMATION AND ITS CYTOTOXICITY IN ACUTE PROMYELOCYTIC LEUKEMIA CELLS.
Y.C. Mun1, J.Y. Ahn1, E.S Yoo2, K.E. Lee1, E. Nam1, S.N. Lee1, S. Oh3, C.M. Seong1
1Department of Internal Medicine, Ewha Womans University School of Medicine, South Korea
2Department of Pediatrics, Ewha Womans University School of Medicine, South Korea
3Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, South Korea
5
DO WE NEED TO INDUCE ALL ACUTE MYELOID LEUKEMIA AND HIGH RISK MDS PATIENTS? BREAKTHROUGH REPORT CHANGING THE PARADIGM OF MANAGEMENT.
K.S. Nataraj1, S. Damodar1, S. Bhat1, S. Badiger1, P. Mondal2
1Heamat-Oncology & Stem Cell Transplantation, Mazumdar Shaw Cancer Center, Natayana Health, India
2Heamatology, Nilratan Sircar Medical College, India
5b ELDERLY PATIENT WITH T(8;21) ACUTE MYELOID LEUKEMIA TREATED WITH AZACYTIDINE
S. S. Medeni, C. Acar, Ö.G. Sevindik, D. Türkyılmaz, S Yiğit Kaya, İ. Alacacıoğlu, Ö. Pişkin, M.A. Özcan, F. Demirkan, H.G. Özsan, B. Ündar
Hematoloji ABD, Dokuz Eylül Üniversitesi, Turkey

Board #
BONE MARROW TRANSPLANTATION
5a
A. Oodi, N. Amirizadeh, M. Nikougoftar
Hematology, Blood Transfusion Research center, High Institute for Education and Research in Transfusion Medicine, Iran
6
SUCCESSFUL MOBILIZATION WITH PLERIXAFOR PLUS GRANULOCYTE COLONY-STIMULATING FACTOR IN PEDIATRIC PATIENTS
J.Y. Choi, J.W. Lee, H.Y Ju, C.R. Hong, H.J. Kang, K.D. Park, H.Y. Shin, H.S. Ahn
Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, South Korea
7
VELOCITY OF MONOCYTE INCREMENT AS APREDICTIVE MARKER FOR TIMING OF AUTOLOGUS STEM CELL COLLECTION
J.C. Jo1, E.H. Lee1, E.K. Kang1, J.H. Lim2, H. Kim1
1Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, South Korea
2Laboratory Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, South Korea
8
J. Chung6
1Internal Medicine, Kosin University College of Medicine, South Korea
2Laboratory Medicine, Kosin University College of Medicine, South Korea
3Occupational and Environmental Medicine, Kosin University College of Medicine, South Korea
4Internal Medicine, Kyungpook National University Hospital, South Korea
5Internal Medicine, Busan Paik Hospital, South Korea
6Internal Medicine, Busan National University Hospital, South Korea

Board #
CHRONIC MYELOID LEUKEMIA (CML)
9
NEW ONSET LEUKOCYTOSIS AND JAK2-V617F MUTATION EVOLVING IN AN AP-CML PATIENT IN COMPLETE CYTOGENETIC REMISSION DURING NILOTINIB TREATMENT
A. Christoforidou1, T. Touloumenidou2, S. Gouliamtzi1, I. Bazdiara1, D. Margaritis1
1Hematology, Democritus University of Thrace, Greece
2Hematology, Papanicolaou General Hospital, Greece
10
PREGNANCY AND CML
A. Işık1, E. Eliaçık1, G. Güneş1, Ü. Malkan1, S. Balaban1, T. Aslan1, S. Etgül1, Y. Z. Şener2, A.A. Erbil2, S. Aksu1, H. Demiroğlu1, H. Göker1, Y. Büyükaşık1, O. Özcebe1, N. Sayınalp1, İ. Haznedaroğlu1
1Division Of Hematology, Hacettepe University, Turkey
2Department Of Internal Medicine, Hacettepe University, Turkey
11
12
CHANGES OF QUALITY OF LIFE AFTER CESSATION OF IMATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL DISEASE
S. Oh1, S Lee2, S Kim3, H Kim4, Y Mun5, D Kim6
1Internal Medicine, Kangbuk Samsung Hospital, South Korea
2Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, South Korea
3Internal Medicine, Dong-A University College of Medicine, South Korea
4Internal Medicine, Ulsan University Hospital, South Korea
5Internal Medicine, Ewha Womans University Hospital, South Korea
6Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, South Korea
12a
M. Saeidifar1, M Eslami-Moghaddam2, A Divsalar3, H Mansouri-Torshizi
1Nanotechnology and Advanced Materials Department, Materials and Energy Research Center, Iran
2Chemistry and Chemical Engineering Research Center, Chemistry and Chemical Engineering Research Center, Iran
3Department of Cell and Molecular Biology, Faculty of Biological Sciences, Iran
13
A. Sofo-Hafizovic, E. Hasanefendic, L. Ibricevic Balic
Department of Hematology, Clinical Center Universtity of Sarajevo, Bosnia and Herzegovina
14
CMPD WITH t(5;12)(q33;p13), ETV/PDGFRB TREATED SUCCESSFULLY WITH IMATINIB MESYLATE
E.L. Tothova1, A. Kafkova2, K. Dyl3, L. Copakova4
1ULKB, UPJS, Kosice, Slovakia
2Dpt of Hematology, HEMKO, Slovakia
3Dpt of Hematology, HTO, Slovakia
4Dpt of Genetic, NOU, Slovakia
15
NILOTINIB INDUCES APOPTOSIS THROUGH JAK/STAT PATHWAY MEMBER STAT5A, STAT5B IN K562 CML CELL MODEL
T. Guliyeva1, B.T. Kaymaz2, M.C. Ozkan1, A.O. Uysal1, B. Kosova2, F. Sahin1,
G. Saydam1
1Hematology, Ege University Hospital, Turkey
2Medical Biology, Ege University Hospital, Turkey
 
Board #
COAGULATION DISORDERS
16 ASSOCIATION OF FACTOR V LEIDEN G1691A AND PROTHROMBIN GENE G20210A MUTATION WITH RECURRENT PREGNANCY LOSS
S. Ali, B. Moiz, L. Shaikh, A. Nasir
Pathology and Microbiology, Aga Kha University, Pakistan
17
FREQUENCY OF FACTOR II G20210A AND FACTOR V LEIDEN MUTATIONS IN ALGERIAN PATIENTS WITH VENOUS THROMBOEMBOLISM
N. Chalal1, A. Demmouche1, Sakina Cherif touil, S. Cherif touil2
1Department of Biology, Djillali Liabes University of Sidi Bel Abbes, Algeria
2Medical laboratory of Sig, Algeria
18
THE RISK OF VENOUS THROMBOEMBOLISM IN ALGERIAN PATIENTS
N. Chalal, A. Demmouche
Department of Biology, Djillali Liabes University of Sidi Bel Abbes, Algeria
18a
R. Elsheikh1, M. Satti2, E. Khalil1
1Department of Clinical pathology & Immunology, Institute of Endemic Diseases, Sudan
2Department of Pathology, Faculty of Medicine, Sudan
19
THERAPEUTIC DECISION ANALYSIS FOR MONITORING UFH THERAPY USING ACTIVATED PARTIAL THROMBOPLASTINE TIME COMPARED WITH ANTI-Xa ASSAY.
W. EL-Neanaey1, Z. Mourad1, W. Shaalan2, M. Faghry3
1clinical pathology, faculty of medicine, Alexandria University,, Egypt
2vascular surgery, faculty of medicine, Alexandria University, Egypt
3vascular surgery, medical military academy, Egypt
20
M. Petit1, M. Baguena1
1Hematology, idcsalut Clinica del Pilar, Spain
2Citology, Hospital Vall de Hebron, Spain
21
STUDY OF CYTOKINE PROFILE IN AUTOIMMUNE THROMBOCYTOPENIA (ITP) OF CHILDHOOD
A. Papagianni1, M. Economou1, E. Farmaki1, V. Tzimouli1, A. Tragiannidis2, E. Karatza3, F. Athanassiadou2, N. Gompakis1,
M. Athanassiou1
11rst Pediatric Department, Ippokration General Hospital, Aristotle University of Thessaloniki, Greece
22nd Pediatric Department, A.X.E.P.A. General Hospital, Aristotle University of Thessaloniki, Greece
33rd Pediatric Department, Ippokration General Hospital, Aristotle University of Thessaloniki, Greece
22
IS WARFARIN SAFE AND EFFECTIVE ENOUGH IN THE 21ST CENTURY?
F. Sasvary, F. Sasvary Jr
Internal Department, General Hospital HOSPITALE, Slovakia
23
VACUOLATING CYTOTOXIN A (VacA) OF HELICOBACTOR PYLORI BINDS TO MULTIMERIN1.
K. Satoh1, T. Hirayama2, M. Ohta3, S. Tamura3, Y. Ozaki3
1Division of Laboratory Medicine, University of Yamanashi Hospital, Japan
2Department of Bacteriology, Institute of Tropical Medicine, Nagasaki University, Japan
3Clinical and Laboratory Medicine, University of Yamanashi, Japan

Board #
HAEMOGLOBINOPATHIES
24
THE STUDY OF THE EFFECT OF CHLORPYRIFOS INSECTICIDES ON BLOOD PROTEINS IN MICE
A. Jalalizand, M. Modaresi, H. Salehi
Biology, Khorasgan (Isfahan) Branch, Islamic Azad University, Iran
25
26
THE EFFECT OF TARAXACUM OFFICINALE HYDRO ALCOHOLIC EXTRACT ON BLOOD PARAMETERS IN MICE
M. Modaresi1, N. Resalatpoor2
1Physiology, Khorasgan (Isfahan) Branch , Islamic Azad University, Iran
2Biology, Payam e Noor University – Isfahan Center, Iran
27
NEUTROPHIL FUNCTION AND HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE
K. Orf1,2, C. Evans1,2, S. Chakrovorty2, A. Cunnington1,2
1Section of Paediatrics, Imperial College London, UK
2Department of Paediatrics, St Mary's Hospital, UK
28
EVALUATION OF HYDROXYUREA THERAPY ON RENAL FUNCTION IN PEDIATRIC PATIENTS WITH SICKLE/BETA-THALASSEMIA
A. Teli, E. Papadopoulou, N. Printza, M. Athanassiou, N. Gompakis, F. Papachristou, M. Economou
First Department of Pediatrics, Aristotle University of Thessaloniki, Greece
29
THALASSEMIA INTERMEDIA IN PEDIATRIC PATIENTS: A 20-YEAR SINGLE CENTER EXPERIENCE
A. Teli1, S. Theodoridou2, A. Papastergiopoulos1, V. Gourtsa1, E. Papadopoulou1,
J.T. Synodinos3, E. Kanavakis3, M. Economou1
1First Department of Pediatrics, Aristotle University of Thessaloniki, Greece
2Hemoglobinopathy Prevention Unit, Hippokration General Hospital, Greece
3Department of Medical Genetics, University of Athens, Greece

Board #
IRON OVERLOAD
30
IRON CHELATION THERAPY WITH DEFERASIROX IN OLDER PATIENTS WITH TRANSFUSION DEPENDENT ANEMIA.
L. Del Corso1, E. Arboscello1, R. Ghio1, R. Tassara2, T. Calzamiglia3, R. Goretti4,
G. Ubezio1, M. Scudeletti1, J. Agnelli Giacchello1
1Dip. Emato-Oncologico, IRCCS-AOU-San Martino-IST, Italy
2Medicina interna, Ospedale San Paolo, Italy
3Medicina Interna, Ospedale di Sanremo, Italy
4Meidina Interna, Ospedale Santa Corona, Italy
31
IS IT NECESSARY TO PERFORM LIVER MRI T2* EARLIER IN PATIENTS WITH THALASSEMIA INTERMEDIA?
A. Jetsrisuparbc1, J Srinakarin2, N. Chaosuwannakit2, P. Hanpanich2, P. Saiviroonporn3, P. Komwilaisak1, S. Wiangnon1
1Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Thailand
2Department of Radiology, Faculty of Medicine, Khon Kaen University, Thailand
3Department of Radiology, Faculty of Medicine, Mahidol University, Thailand

Board #
LYMPHOMA
32
CLINICAL FEATURE AND TREATMENT PATTER OF FOLLICULAR LYMPHOMA IN KOREA
S.H. Cho1, S. Young Oh2, W.S. Kim3
1Hematology-Oncology, Pusan national university Yangsan hospital, South Korea
2Hematology-Oncology, Dong-A university college of medicine, South Korea
3Hematology-Oncology, Samsung medical center, South Korea
33
34
MULTIPLE NEOPLASMS CONSIST OF GASTRIC CANCER AND HEMATOLOGICAL MALIGNANCY
N. Kazuhiko, S. Ishihara, D. Nagase, A. Sakai, M. Kato, Y. Kuraishi, H. Izumi
Hematology & Oncology, Toho university Medical Center Oomori Hospital, Japan
35
ORAL INFECTION CONTROL IN ELDERLY MALIGNANT LYMPHOMA PATIENTS
N. Kazuhiko1, S. Ishihara1, D. Nagase1, A. Sakai1, M. Kato1, Y. Kuraishi1, K. Arai2,
H. Izumi1
1Division of Hematology&Oncology, Toho university Medical Center Oomori Hospital, Japan
2Faculty of Nursing, Toho university, Japan
36
PROGNOSTIC SIGNIFICANCE OF SYSTEMIC INFLAMMATORY FACTORS IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA TREATED BY R-CHOP
H. Sup Lee1, C. Kim1, C. Lee1, E. Lee1, S. Shin1, B. Ye1, J. Moon2, J. Jo3, W. Lee4,
H. Shin5, S. Oh6, Y. Kim1
1Internal medicine, Kosin University College of Medicine, South Korea
2Internal medicine, Kyungpook National University Hospital, South Korea
3Internal medicine, University of Ulsan College of Medicine, South Korea
4Internal medicine, Busan Paik Hospital, South Korea
5Internal Medicine, Busan National University Hospital, South Korea
6Internal medicine, Dong-A University Hospital, South Korea
36a
E. KIZILKILIC1, N. Yener2, B. Ersoy3, G. Sezgin4
1Department of Hematology, maltepe University Medical School, Turkey
2Department of Pathology, maltepe University Medical School, Turkey
3Department of Plastic Surgery, Maltepe University Medical School, Turkey
4Department of Internal Medicine, maltepe University Medical School, Turkey
37 PRIMARY EXTRANODAL NON-HODGKIN'S LYMPHOMA: CLINICOPATHOLOGICAL FEATURES, SURVIVAL AND TREATMENT OUTCOME IN TWO CANCER CENTERS OF SOUTHERN TURKEY.
H. Mertsoylu1, S. Muallaoglu1, A. Ayberk Besen1, S. Erdogdu2, A. Sezer1,
A. Murat Sedef1, F. Kose1, A. Arıcan1, O. Ozyilkan1
1Medical Oncology, Baskent University, Turkey
2Medical Oncology, Mersin University, Turkey
38
B. Onec1, N. Unlu2, M. Oktay3, M. Köş4
1Department of Hematology, Düzce University of Medicine, Turkey
2Department of Radiology, Düzce University of Medicine, Turkey
3Department of Pathology, Düzce University of Medicine, Turkey
4Department of Internal Medicine, Düzce University of Medicine, Turkey
39
TREATMENT OUTCOME OF ESHAP SALVAGE CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA WHO HAD NOT UNDERGONE AUTOLOGOUS STEM CELL TRANSPLANTATION
Y. Park1, J.S. KIM1, D.S. KIM1, S.R. LEE1, H.J. SUNG1, S.J. KIM2, C.W. CHOI1, B.S. KIM1
1Department of Hematology, Korea University School of Medicine, South Korea
2Department of Hematology-Oncology, Samsung Medical Center, South Korea

Board #
MULTIPLE MYELOMA (MM)
40
PLASMA CELL NEOPLASM WITHOUT DETECTABLE LIGHT CHAINS: A CLINICOPATHOLOGIC, IMMUNOPHENOTYPIC, AND CYTOGENETIC STUDY OF 36 CASES
H. Drum1, E. Wei3, P. Petersen2, K. Bourbeau2, B. Dabbas1, D. Rezania1
1Cartesian, Genoptix Medical Laboratory, a Novartis Company, USA
2Clinical Services Coordinator, Genoptix Medical Laboratory, a Novartis Company, USA
3Hematopathology, NeoGenomics Laboratories, USA
41
B. Onec1, E. Saribacak Can2, V. Aslan2, M. Albayrak2, H. Okutan2, M. Köş3, A. Albayrak4
1Department of Hematology, Düzce University of Medicine, Turkey
2Department of Hematology, Dışkapı Training and Research Hospital, Turkey
3Department of Internal Medicine, Düzce University of Medicine, Turkey
4Department of Pathology, Dışkapı Training and Research Hospital, Turkey
42
A. U. Oruc, M. C. Ozkan, F. Sahin, F. Vural, M. Tobu, M. Tombuloglu, G. Saydam
Hematology, Ege University Hospital, Turkey
43
MULTIPLE MYELOMA IN AN 11 YEAR OLD BOY: A CASE REPORT
M. Economou, A. Papagianni1, D. Adamidou3, K. Pagioula, S. Stambouli,
A. Taparkou, A. Anastasiou2, N. Gompakis, F. Papachristou
11rst Pediatric Department, Ippokration General Hospital, Aristotle University of Thessaloniki, Greece
2Radiology Department, Ippokration General Hospital, Greece
3Blood bank, Ippokration General Hospital, Greece
44
INCIDENCE OF INFECTION ACCORDING TO INTRAVENOUS IMMUNOGLOBULIN (IVIG) USE IN AUTO-HCT RECIPIENTS WITH MULTIPLE MYELOMA
S. Park1, S.H. Cho2, J. Ho Jang1, C. Won Jung1, K. Kim1
1Internal medicine, Samsung Medical Center, South Korea
2Internal medicine, Pusan national university Yangsan Hospital, South Korea
44a
K. Papadopoulos1, D. Siegel2, D. Vesole2, P. Lee3, N. Zojwalla4, J. Lee5, A. Badros6
1Hematology, South Texas Accelerated Research Therapeutics, USA
2Myeloma Division, John Theurer Cancer Center at Hackensack University Medical Center, USA
3Hematology/Oncology, Tower Cancer Research Foundation, USA
4Medical Affairs, Onyx Pharmaceuticals, Inc., an Amgen subsidiary, USA
5Biostatistics, Onyx Pharmaceuticals, Inc., an Amgen subsidiary, USA
6Blood and Marrow Transplantation, Greenebaum Cancer Center at University of Maryland School of Medicine, USA

Board #
MYELODYSPLASTIC SYNDROME (MDS)
45
REVERSAL OF MYELODYSPLASIA WITH PITUITARY HORMONE REPLACEMENT
I. Mehta1, K. Patel2, M. Edwards1
1Diabeticare, The Hillingdon Hospitals NHS Foundation Trust, UK
2Department of Haematology, The Hillingdon Hospitals NHS Foundation Trust, UK
45a A NOVEL TRANSLOCATION T(1;18) IN A PATIENT WITH MYELODYSPLASTIC SYNDROME
S. S. Medeni, C. Acar, Ö.G. Sevindik, D. Türkyılmaz, S. Yiğit Kaya, İ. Alacacıoğlu, Ö. Pişkin, M.A. Özcan, H. G. Özsan, F. Demirkan, B. Ündar
Hematoloji ABD, Dokuz Eylül Üniversitesi, Turkey

Board #
MYELOPROLIFERATIVE DISEASES (MPN)
46
PREGNANCIES IN WOMEN SUFFERING FROM ESSENTIAL THROMBOCYTHEMIA OR POLYCYTHEMIA VERA
M. Kuliszkiewicz-Janus1, J. Kwiatkowski1, R. Małecki2, J. Kolosko1
1Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Poland
2Department of Angiology, Hypertension and Diabetology, Wroclaw Medical University, Poland
47
IS JAK2V617F MUTATION THE ONLY CULPRIT FOR VENOUS THROMBOSIS IN PHILADELPHIA-NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS?
G. Emel Pamuk1, M.S. Uyanik1, M. Baysal2, M. Maden1
1Department of Hematology, Trakya University Medical Faculty, Turkey
2Department of Internal Medicine, Trakya University Medical Faculty, Turkey

Board #
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
48
RICHTER SYNDROME OR SECOND MALIGNANCY IN PATIENT WITH CLL
L. Kriachok, K. Fionenko, I. Stepanishyna, Y. Pastushenko

Oncohematology, National Cancer Institute, Ukraine